Does microgranular variant morphology of acute promyelocytic leukemia independently predict for a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, González J, Feusner JH, González M, Gallagher R, González-San Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA. Blood 116(25):5650-9. FI: 10.555 (Q1) Primary cutaneous localized amyloid elastosis Santos-Briz A, Cañueto J, Antúnez P, Bravo J, García-Sanz R, de Unamuno P. American Journal of Dermatopathology 32(1):86-90. FI: 1.295 (Q3 Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, Leal da Costa F, García-Sanz R, Schey S, Facon T, Morgan G, Moreau P. Annals of Hematology 89(8):803-11. FI: 2.919 (Q2) A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF. Spanish Hodgkin Lymphoma Study Group. Blood 116(8):e12-7. FI: 10.555 (Q1) The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, García-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG.International Myeloma Working Group. Leukemia 24(10):1700-12. FI: 8.296 (Q1) Monoclonal free light chains can be found in heavy chain diseases López-Anglada L, Puig N, Díez-Campelo M, Alonso-Ralero L, Barrena S, Aparicio MA, Gutiérrez NC, García-Sanz R. Annals of Clinical Biochemistry 47(Pt6):570-2. FI: 1.917 (Q2) BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML) Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M. Annals of Hematology 89(5):453-8. FI: 2.919 (Q2) Long FLT3 internal tandem duplications and reduced PML-RARa expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, María Eugenia S, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, de Coca AG, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M. Haematologica 95(5):745-51. FI: 6.416 (Q1) Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA. Haematologica 95:424-31. FI: 6.416 (Q1) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Fermiñán E, Martín-Jiménez P, Chillón C, Risueño A, Hernández JM, García-Sanz R, González M, San Miguel JF. Leukemia 24:629-37. FI: 8.296 (Q1)
|
